News Center
With the tenet of "Healthy China, Dedicated commitment", Linuo Pharmaceuticals increases cooperation and association with external scientific research institutes while innovating and developing independently.
07
2025
-
07
Chasing Dreams Among the Stars, Returning in Glory! The 2025 Starry Night Conference concludes, and a new product from Linoa Pharmaceuticals, a subsidiary of Keyuan Pharmaceuticals, wins another award!
Classification：
行业新闻
Corporate News
7 On March 3, the highly anticipated 2025 Xingchen Conference came to a successful close. As the annual event for the pharmaceutical industry, the Xingchen Conference attracted numerous well-known domestic and international companies to exhibit, jointly exploring industry development trends and showcasing cutting-edge products and technologies. Lino Pharmaceuticals, with its full matrix of products, was invited to exhibit and achieved fruitful results in new product launches and brand building.
At the exhibition site, Li Hongfu, Chairman of Lino Pharmaceuticals, led the team in cordial exchanges with partners from across the country. The company's core products on display covered several important therapeutic areas, including cardiovascular, anti-diabetic, and central nervous systems. Several recently launched new products also became the focus of the exhibition, such as Ferric Protein Succinate Oral Solution for the treatment of iron deficiency anemia, Ambroxol Hydrochloride Droplets for children's cough, Minoxidil Lotion, and Fudosteine Oral Solution. These new products, with their unique formulas, excellent efficacy, and good safety, won high recognition and favor from industry experts and new and old partners as soon as they were exhibited, laying a solid foundation for the company's market expansion and in-depth layout.
During the exhibition, Lino Pharmaceuticals won the "Strategic Partner" honor at the conference for its outstanding market performance, innovation capabilities, and positive contributions to industry development. This is a high affirmation of Lino Pharmaceuticals' brand strength and recognition of its long-term commitment to technology-driven development and providing high-quality pharmaceutical products to patients.
In addition, Lino Pharmaceuticals' new product, Ambroxol Hydrochloride Droplets, stood out among numerous exhibited products and won the "Xingchen 5th Anniversary Recommended Product" honor. This product has received widespread market attention since its launch. Previously, at the "Wuzhen Health Conference," which concluded in April, Ambroxol Hydrochloride Droplets was honorably listed as the "West Lake Award - Most Popular Star Single Product among Retail Pharmacies." This latest award further demonstrates the product's market value and industry influence.
The excellent performance at the Xingchen Conference is the result of the company's years of commitment to technological innovation and quality. In the future, Lino Pharmaceuticals will continue to increase R&D investment, continuously enrich its product matrix to meet the health needs of different patient groups. At the same time, the company will further deepen cooperation with all sectors of the industry, working together to contribute to the high-quality development of the pharmaceutical industry.
Related news
ADD：#30766 Jingshidong Road, Linuo High-tech Park, Jinan, Shandong Province, P. R. China
